Mood
Conditions
Brief summary
There is a growing interest within the scientific community of whether prebiotics can aid in clinical outcomes including mood via modulation of the gut microbiota and its resulting metabolites via the gut-brain axis. This is especially prevalent given that mental health conditions are associated with cost and burden on the health care system. Yet, to date very few studies have investigated the potential effects of prebiotics to influence mood via the modulation of the gut microbiota with previous studies recording mixed results indicating further work in this area would be highly beneficial.
Detailed description
Several reports have suggested that poor mental health among university students is on the increase. Factors driving this; including academic pressure, overdemanding workloads, financial concerns, and peer pressure; can adversely affect academic performance and self-worth. Thus, there is an increasing need to develop new strategies to help tackle these modalities while also reducing the burden on the health system. In recent years there has been increasing interest in the bi-directional relationship that exists between the gut and the brain, a term coined the gut-brain axis, and it is suggested to play a role in influencing mood via chemical messengers. As diet is key manipulator of the gut microbiota one way to influence the composition of the gut is via diet and the use of functional foods including prebiotic oligosaccharides. The idea that functional foods like prebiotics may help to affect mood holds particular appeal due to them being relatively free of side effects, cheap, readily accessible and possessing additional health benefits including improving bowel transit function and improving satiety amongst others. Yet, to date previous research on the potential for prebiotics has produced mixed results due to differences in the populations tested, doses and types of prebiotics used, and means of assessing changes in mood suggesting further work in this area would be highly beneficial. Therefore, this present study aims to address the question can manipulation of the gut microbiota using prebiotic oligosaccharides alone or in combination influence mental state in a taught university student population?.
Interventions
DIETARY_SUPPLEMENTPlacebo
maltodextrin taken daily for 4 weeks with water
DIETARY_SUPPLEMENTPrebiotic supplement
Prebiotic supplement taken daily for 4 weeks with water
DIETARY_SUPPLEMENTPrebiotic combination
prebiotic oligosaccharides mixture taken daily for 4 weeks with water
DIETARY_SUPPLEMENTPrebiotic oligosaccharides
Prebiotic oligosaccharides taken daily for 4 weeks with water
Sponsors
University of Reading
Beneo-Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Volunteer is healthy at the time of pre-examination * Possess mild/moderately elevated levels of stress * Volunteer is aged ≥ 18 to ≤ 45 years at the time of pre-examination * Volunteer's BMI is ≥ 18.5 and ≤ 29.9 * Volunteer has a stool frequency of at least 3 bowel movements per week * Volunteer is able and willing to comply with the study instructions * Volunteer is suitable for participation in the study according to the investigator/study personnel * Written informed consent is given by volunteer
Exclusion criteria
* No command of any local language * Previously or currently diagnosed neurological or psychiatric disorders * Previous history of renal, hepatic, cardiovascular disease or clinically significant diabetes * Gastrointestinal disorders including IBS, IBD or other conditions that might affect the gut environment * Food allergies or intolerances * Using drugs (e.g. antibiotics, aspirin, proton pump inhibitors) influencing gastrointestinal function (8 weeks before intervention) * Use of laxatives and labelled pre-and probiotics in the previous 4 weeks before the beginning of intervention * Volunteers currently involved or will be involved in another clinical or food study * History of drug (recreational) or alcohol abuse. * Use of anti-depressants medication including selective serotonin receptor inhibitors or Amitriptyline for 3 months prior to commencing the trial * Received bowel preparation for investigative procedures in the 4 weeks prior to the study * Undergone surgical resection of any part of the bowel. * pregnant or lactating
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bifidobacterium spp in stool samples | 4 weeks | Bifidobacterium spp. will be assessed in stool samples by molecular biological methods |
| Anxiety with State-Trait Anxiety Inventory questionnaire | 4 weeks | Anxiety will be assessed with anxiety questionnaire at baseline and at the end of intervention |
| Depression with Beck's Depression Inventory questionnaire | 4 weeks | Depression will be assessed with depression questionnaire at baseline and at the end of intervention |
| Salivary IgA | 4 weeks | Salivary IgA will be assessed by ELISA at baseline and at the end of intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urinary Metabolites (organic compounds) concentration | 4 weeks | Urinary Metabolites concentration will be assessed at baseline and end with NMR |
| Gastrointestinal sensations (bloating) | 5 weeks | Gastrointestinal sensations (bloating) will be assessed in a daily diary during baseline and intervention periods on a 4-point Likert scale (higher scores indicate higher sensation) |
| Gastrointestinal sensations (flatulence) | 5 weeks | Gastrointestinal sensations (flatulence) will be assessed in a daily diary during baseline and intervention periods on a 4-point Likert scale (higher scores indicate higher sensation) |
| Changes in microbiota composition | 4 weeks | Microbiota composition at baseline and end will be assessed by 16S rRNA gene sequencing |
| Gastrointestinal sensations (fullness) | 5 weeks | Gastrointestinal sensations (fullness) will be assessed in a daily diary during baseline and intervention periods on a 4-point Likert scale (higher scores indicate higher sensation) |
| Sleep quality via The Pittsburgh Sleep Quality Index | 4 weeks | Sleep quality will be assessed at baseline and end with The Pittsburgh Sleep Quality Index questionnaire |
| Gastrointestinal sensations (abdominal pain) | 5 weeks | Gastrointestinal sensations (abdominal pain) will be assessed in a daily diary during baseline and intervention periods on a 4-point Likert scale (higher scores indicate higher sensation) |
| Total bacteria in stool samples | 4 weeks | Total bacteria will be assessed in stool samples by molecular biological methods |
| Stool frequency | 5 weeks | Stool frequency will be assessed as effective number of bowel movements in a daily diary during baseline and intervention periods |
| Stool consistency according to Bristol Stool Form Scale | 5 weeks | Stool consistency will be assessed in a daily diary during baseline and intervention periods |
Countries
United Kingdom
Outcome results
None listed